Trials / Completed
CompletedNCT04370379
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI302 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed for multi-center, open-label, randomized, dose escalation phase I trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of IBI302 in neovascular AMD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI302 (the first dose level) | q4week (3 injections) followed by PRN dosing |
| DRUG | IBI302 (the second dose level) | q4week (3 injections) followed by PRN dosing |
| DRUG | Aflibercept | 2mg, q4week (3 injections) followed by q8week |
Timeline
- Start date
- 2020-05-28
- Primary completion
- 2021-04-30
- Completion
- 2021-05-08
- First posted
- 2020-04-30
- Last updated
- 2021-11-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04370379. Inclusion in this directory is not an endorsement.